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Abstract
Background: Recent evidence suggests that glycogen synthase kinase-3b (GSK3b) is implicated in both sporadic
and familial forms of Alzheimer’s disease. The transcription factor, p53 also plays a role and has been linked to an
increase in tau hyperphosphorylation although the effect is indirect. There is also evidence that GSK3b and p53
interact and that the activity of both proteins is increased as a result of this interaction. Under normal cellular
conditions, p53 is kept at low levels by Mdm2 but when cells are stressed, p53 is stabilised and may then interact
with GSK3b. We propose that this interaction has an important contribution to cellular outcomes and to test this
hypothesis we developed a stochastic simulation model.
Results: The model predicts that high levels of DNA damage leads to increased activity of p53 and GSK3b and low
levels of aggregation but if DNA damage is repaired, the aggregates are eventually cleared. The model also shows
that over long periods of time, aggregates may start to form due to stochastic events leading to increased levels
of ROS and damaged DNA. This is followed by increased activity of p53 and GSK3b and a vicious cycle ensues.
Conclusions: Since p53 and GSK3b are both involved in the apoptotic pathway, and GSK3b overactivity leads to
increased levels of plaques and tangles, our model might explain the link between protein aggregation and
neuronal loss in neurodegeneration.
Background
Glycogen synthase kinase-3 (GSK3) is a protein kinase
involved in many physiological processes including cell
structure, metabolism, gene expression and apoptosis.
There are two forms of GSK3 - GSK3a and GSK3b
both of which are ubiquitously expressed and constitu-
tively active. Many of GSK3’s substrates require pre-
phosphorylation (priming) and so activity of priming
kinases may limit GSK3 activity. GSK3 activity is also
inhibited by insulin and Wnt signalling.
GSK3 has been implicated in both sporadic and famil-
ial forms of Alzheimer’s disease (AD) and this recently
led Hooper et al. to put forward the ‘GSK3 hypothesis
of AD’ [1]. This hypothesis proposes that over activity
of GSK3 accounts for tau hyper-phosphorylation,
increased production of Ab, inflammatory responses,
reduction in acetylcholine synthesis, and memory
impairment, all typical features of AD. GSK3 is also a
key mediator of apoptosis but some studies show
opposing effects on apoptosis (e.g. [2,3]). A solution to
this paradox is that GSK3 has a pro-apoptotic effect on
the intrinsic pathway but an anti-apoptotic effect on the
extrinsic pathway [4].
The tumour suppressor protein, p53, is well known
for its role in cell cycle arrest, DNA repair and apoptosis
and is the most frequently mutated gene in human can-
cer. It is also plays an important role in ageing [5]. A
role for p53 in neurodegeneration is less well known
but several studies have reported an increase in p53
immunoreactivity in sporadic AD (cited in Hooper et al)
[6] especially in subpopulations of cortical neurons
undergoing neurofibrillary degeneration. It has recently
been demonstrated that expression of p53 is partly
mediated by the intracellular, transcriptionally active
domain of the Amyloid Precursor Protein (APP) [7] and
also that Ab, especially Ab42 binds to the p53 promoter
and enhances transcription [8]. An interesting observa-
tion by Hooper et al (2007) is that p53 induces tau
phosphorylation but that the effects are indirect since
they observed p53 in the nucleus and tau in the cytoske-
letal compartment [6]. Such effects could either be due
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a p53 signalling pathway. One possibility is that GSK3b
is the kinase responsible for the p53-induced tau phos-
phorylation, since p53 affects GSK3b activity. This paper
focuses on this possible link which is described further
below.
AD is characterised by the presence of extracellular
amyloid plaques and intracellular tangles of which tau is
the principal component. There is controversy over
whether these plaques and tangles are toxic to cells or
whether they are in fact a protective mechanism. The
main consensus is that the intermediate soluble oligo-
mers are the most harmful as these interfere with the
cellular machinery. In particular they may bind to pro-
teasomes and inhibit proteasomal function. Proteasomes
are required for the turnover of regulatory short-lived
proteins such as p53 and so any decline in proteasomal
function may have severe consequences for cellular
homeostasis. Oxidised and damaged/misfolded proteins
are also degraded by proteasomes, so less efficiency of
this system may result in aggregation of other misfolded
proteins, apart from Ab and tau. Aggregated protein
inhibits proteasomal function with small soluble oligo-
mers being the most toxic. For example, Tseng et al
(2008) [9] show that small oligomers but not monomers
of Ab inhibit proteasomes. Similarly, it has been shown
that paired helical filaments of tau inhibit the protea-
some [10].
Tau protein binds and stabilises microtubules (MT)
but it also has to disassociate to allow trafficking of
other molecules along MTs and so the interaction is
dynamic. A widely held view is that phosphorylation of
tau induces aggregation since tau tangles often contain
hyperphosphorylated tau. However, it has been shown
that phosphorylation does not directly increase the pro-
pensity of tau to form aggregates [11,12] but rather that
the effect is due to increased pools of unbound tau
since phosphorylated tau is unable to bind to microtu-
bules. Tau is phosphorylated by several different kinases
b u tt h eC d k 5a n dG S K 3 b kinases phosphorylate the
sites which are implicated in AD [13]. Normal tau is
also turned over by the 20S proteasome with a half-life
of about 12-14 hours [14], whereas phosphorylated tau
may be ubiquitinated and degraded by the 26S
proteasome.
Link between GSK3 and p53
It has been shown that apoptotic stimuli induce nuclear
accumulation of GSK3b colocalising it with p53 [15].
This study reported that there was no nuclear accumu-
lation of GSK3b after DNA damage (induced by camp-
tothecin treatment) but rather an exclusive activation of
the nuclear pool with no activation of cytosolic pools.
The authors showed that p53 coimmunoprecipitates
with GSK3b from nuclear fractions after camptothecin
treatment. They found that binding of p53 directly
increases activity of GSK3b, and that the activated
GSK3b contributes to transcriptional activity of p53.
Another study showed that GSK3 can regulate p53
levels through the phosphorylation of Mdm2 [16]. GSK3
phosphorylates sites in the central domain of Mdm2
and this phosphorylation is required for p53 degrada-
tion. Inhibition of GSK3 leads to an increase in p53
levels. However p53 still binds to and is ubiquitinated
by Mdm2 after GSK3 inhibition suggesting that there is
a post-ubiquitination role of Mdm2 for p53 degradation.
Both GSK3 and p53 are degraded by the ubiquitin-
proteasome system. GSK3b is a relatively stable protein
with a half-life of about 48 hours [17], whereas p53 is a
relatively unstable protein with a half-life of 20-30 min-
utes under normal cellular conditions. It has been
shown that the function of the ubiquitin-proteasome
system declines with age and so we would expect this to
have an impact on protein turnover and perhaps to
explain the increased level of p53 observed in the ageing
brain. In particular, as mentioned earlier, the protea-
some is inhibited by aggregated protein and so protea-
some capacity may become overwhelmed in time.
The GSK3/p53 Hypothesis of AD (an extension of
the GSK Hypothesis)As previously discussed, under nor-
mal conditions, GSK3b is involved in the regulation of
p53 by phosphorylating Mdm2 which allows p53 protea-
somal degradation to proceed and hence low basal levels
of p53 are maintained. However, under conditions of
cellular stress, p53-Mdm2 complexes are disrupted and
p53 is stabilised. During ageing, proteasome function
also declines partly as a result of the accumulation of
aggregated protein, resulting in increased levels of p53.
This provides a sufficient pool of p53 for binding to
GSK3b leading to increased activity of GSK3b.T h i si n
turn leads to an increase p53 activity leading to a posi-
tive feedback loop. The increase in GSK3b activity also
leads to hyper-phosphorylation of tau and increased
production of amyloid. This will lead to further inhibi-
tion of proteasome function and an ever increasing
spiral ensues. The expected outcome would be apoptosis
via the intrinsic pathway. In this scenario, the initiating
event is either a DNA damage response or a decline in
proteasome function. This is a very complex system and
so we have summarised the key components in Figure 1.
Methods
To build a quantitative model of the system it is neces-
sary to specify all the molecular components of the sys-
tem and the interactions between the different
components. A mathematical model does not need to
include every component and reaction in a system as
this would make the model too complex to aid
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enough detail to make it biologically realistic. It is gen-
erally best to start by keeping the model as simple as
possible and then to add more detail if required. Using
the Systems Biology Markup Language (SBML) to build
the model is ideal for this approach [18]. SBML is a
computer-readable format for representing biochemical
reaction networks and complies to modelling standards
allowing models to be portable and shared by the scien-
t i f i cc o m m u n i t y .T h e r ea r em a n yo p e ns o u r c et o o l s
available for building and simulating SBML models. We
have developed our own system at Newcastle University,
known as BASIS (Biology of Ageing e-Science Integra-
tion and Simulation system) [19,20]. We used SBML
shorthand to code the model and then converted it to
full SBML using a Python script [21]. The model is pub-
licly available on the BASIS website [22] and at the Bio-
models database [23,24]. (Biomodel ID:
MODEL0910130002). The SBML code is also available
as supplementary material (See additional file 1: SBML
code for GSK3-p53 model with IR event).
Most computer simulation models of biological sys-
tems use a deterministic approach which involves sol-
ving a set of differential equations to find the steady
state of the system. However, this approach is not suita-
ble for this model, since we are interested in the varia-
bility of cellular outcomes. For example, the time at
which aggregates start to form in cells will be very
Figure 1 GSK3/p53 hypothesis for AD. A Under normal conditions p53 is bound to Mdm2 which ubiquitinates and targets p53 for
proteasomal degradation. B Under conditions of stress, p53 is stabilised and it can form complex with GSK3b. This results in increased activity of
GSK3b which leads to hyperphosphorylation of tau and increased production of Ab.A b affects p53 pools by increasing its transcription rate and
through inhibition of the proteasome. Note that we also assume that GSK3b can also bind to phosphorylated p53.
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affected by random processes. Therefore, we use sto-
chastic simulation based on the Gillespie algorithm [25].
This means that the output of each simulation run is
different for the same set of initial conditions and para-
meter values, unlike a deterministic simulation which
always produces the same results.
The model of the p53/Mdm2/ATM circuit (Proctor &
Gray 2008) [26] was extended to include details of
GSK3b,A b and tau. The earlier model [26] was devel-
oped to explain the oscillatory behaviour in MCF7 cells
with data supplied by Uri Alon [27]. It contained details
of p53 and Mdm2 turnover but the reactions for protein
degradation were simplified and did not include details
of ubiquitination. Since GSK3b is involved in p53 degra-
dation via phosphorylation of Mdm2 which is in com-
plex with polyubiquitinated p53, it is necessary to add
these steps. A model of the ubiquitin-proteasome has
already been developed (Proctor et al 2007) [28] and so
parts of this model were incorporated into the p53
model. Figure 2 shows a diagram of the overall reaction
system with the important parts of the network shown
in red. Table 1 lists all the species in the model, Table 2
shows all the reactions concerning GSK3b,A b and tau
and Table 3 shows the reactions involved in p53 and
Mdm2 turnover. The previous p53/Mdm2 model
included a module for DNA damage to mimic the
experimental system of irradiating cells and the emer-
gence of oscillations in p53 and Mdm2 after damage.
We considered two mechanisms which led to these
oscillations: sequestering of Mdm2 from the p53/Mdm2
complex by the oncoprotein ARF; or activation of ATM
which then phosphorylated both p53 and Mdm2 and so
inhibits their binding. Either mechanism leads to an
increase in levels of p53 which is followed by an
increase in Mdm2 levels. As Mdm2 levels rose, com-
plexes of p53/Mdm2 are able to reform leading to an
increase in p53 degradation and so levels decrease again
(see Proctor & Gray [26] for full details of modelling the
oscillatory behaviour of p53, and Lahav et al [29] for the
experimental details). This negative feedback loop leads
to oscillations, which persist as long as DNA damage
remains, keeping cells in an arrested state while DNA is
repaired. The oscillations also prevent p53 levels reach-
ing levels which would trigger apoptosis.
GSK3b has a relatively long half-life (about 48 hours)
[17] and like p53, it is turned over by the proteasome. It
has been shown that Hsp90 maintains the stability of
GSK3b [30]. This study also showed that Hsp90 inhibi-
tion results in proteasome-dependent degradation of
GSK3b, and subsequently reduces tau phosphorylation.
However, we chose not to include GSK3b turnover in
this model because it would be stable under the condi-
tions we are simulating and we aim to keep the model
as simple as possible. GSK3b binds to p53 and we
assume that it binds to either phosphorylated or unpho-
sphorylated p53 but that it does not bind to p53/Mdm2
complexes. GSK3b has higher activity when bound to
p53. p53 bound by GSK3b also has increased transcrip-
tional activity, as shown by Watcharisit et al. (2003) [31]
whereby inhibition of GSK3b leads to 50% reduction in
Mdm2 mRNA.
We assume that GSK3b phosphorylates tau with
increased activity if GSK3b is bound to p53. We also
include de-phosphorylation of tau by a phosphatase. We
also assume that GSK3b_p53 produces Ab,h o w e v e r ,
under normal conditions Ab is removed by degradation
and does not accumulate. We expect that under condi-
tions of stress, levels of GSK3b_p53 would increase and
that there would also be increased Ab production. Ab
may form small aggregates which could either inhibit
proteasomes or form plaques. We assume that plaques,
being outside the cell, do not interfere with protea-
somes. We also assume that Ab increases the transcrip-
tion of p53. We assume that tau is normally bound to
microtubules but that binding is prevented when tau is
phosphorylated. We also include tau turnover in the
model and assume that unphosphorylated tau is
degraded by the proteasome without the need for
ubiquitination.
The parameter values were taken from experimental
data where possible. For example we set the degradation
rates for p53, Mdm2 and tau based on their half-life of
20 minutes, 30 minutes and 12 hours respectively and
then set the synthesis rates so that the proteins stayed
at basal levels under unstressed conditions. We set
aggregation rates to be low so that no aggregation
would take place under unstressed conditions. It is
known that phosphorylation reactions take place on
time scales in the order of minutes so we assumed that
these reactions are fast. Further details of the parameters
involved in the DNA damage response are given in [26].
Where parameter values are unknown, the values were
adjusted so that the system was at steady state under
unstressed conditions. The model was validated by
checking the model predictions for levels of p53 and
Mdm2 after the irradiating event.
Results
Model predictions for normal conditions
As we used stochastic simulation, each simulation run
produces different output for the same set of initial con-
ditions. Therefore, it is necessary to carry out repeat
simulations to examine the variability. The model out-
put for 4 individual runs is shown in Figure 3A-D.
When there is no cellular stress, no DNA damage
occurs, p53 levels remain low and p53 is in complex
with Mdm2. Therefore, only very low levels of GSK3b
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Page 4 of 15Figure 2 Network diagram of the model. A Reactions involved in p53 and Mdm2 turnover, and the interaction of p53 with GSK3b.N o ta l l
reactions involving Mdm2 degradation are included as these are similar to the reactions for p53. B Reactions involved in tau turnover and
aggregation. C Reactions involved in Ab production and aggregation, and the DNA damage response. Important reactions for this model are
shown in red. Dashed lines from a species indicate that the species is a modifier of the reaction. Reaction numbers correspond to the numbers
in the first column of Tables 2 and 3.
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Name Description Database term Initial amount
GSK3b Unbound GSK3b protein P49841 500
GSK3b_p53 GSK3b bound to p53 P49841, P04637 0
GSK3b_p53_P GSK3b bound to phosphorylated p53 P49841, P04637 0
p53 Unbound p53 protein P04637 5
Mdm2 Unbound Mdm2 protein Q00987 5
Mdm2_p53 Mdm2/p53 complex Q00987, P04637 95
Mdm2_mRNA Mdm2 messenger RNA SBO:0000278 10
p53_mRNA p53 messenger RNA SBO:0000278 10
p53_P Phosphorylated p53 P04637 0
Mdm2_P Phosphorylated Mdm2 Q00987 0
Ub Ubiquitin P62988 4000
E1 Ubiquitin activating enzyme IPR000011 100
E2 Ubiquitin conjugating enzyme IPR000608 100
E1_Ub E1 bound by Ub IPR000011, P62988 0
E2_Ub E2 bound by Ub IPR000608, P62988 0
p53DUB Deubiquitinating enzyme for p53 IPR001394 200
Mdm2DUB Deubiquitinating enzyme for Mdm2 IPR001394 200
Mdm2_p53_Ub Monoubiquitinated p53 Q00987, P04637, P62988 0
Mdm2_p53_UbX (X = 2-4) Polyubiquitinated p53 Q00987, P04637, P62988 0
Mdm2_P1_p53_Ub4 Phosphorylated Mdm2 bound to p53 Q00987, P04637, P62988 0
Mdm2_Ub Monoubiquitinated Mdm2 Q00987, P62988 0
Mdm2_P_Ub Monoubiquitinated phospho-Mdm2 Q00987, P62988 0
Mdm2_UbX (X = 2-4) Polyubiquitinated Mdm2 Q00987, P62988 0
Mdm2_P_UbX (X = 2-4) Polyubiquitinated phospho-Mdm2 Q00987, P62988 0
Proteasome 26S Proteasome complex GO:0000502 500
p53_Ub4_Proteasome p53 bound to proteasome P04637, P62988, GO:0000502 0
Mdm2_Ub4_Proteasome Mdm2 bound to proteasome Q00987, P62988, GO:0000502 0
Mdm2_P_Ub4_Proteasome phospho-Mdm2 bound to proteasome Q00987, P62988, GO:0000502 0
ATMI Inactive ATM Q13315 200
ATMA Active ATM Q13315 0
damDNA Amount of damaged DNA CHEBI16991 0
IR Dummy species to represent gamma-irradiation - 0
ROS Reactive oxygen species CHEBI:26523 0
basalROS Basal pool of ROS CHEBI:26523 10
Abeta Amyloid beta P05067 0
AggAbeta Small aggregate of Ab P05067 0
AbetaPlaque Ab plaque P05067 0
AggAbeta_Proteasome AggAbeta bound to the proteasome P05067, GO:0000502 0
Tau tau IPR002955 IPR002955 0
Proteasome_Tau tau bound to 20S proteasome GO:0000502, 0
Tau_P1 tau phosphorylated by GSK3b at one site IPR002955 0
Tau_P2 tau phosphorylated by GSK3b at two sites IPR002955 0
MT_Tau tau bound to the microtubule IPR015562 100
AggTau small aggregate of tau IPR002955 0
AggTau_Proteasome AggTau bound to proteasome IPR002955, GO:0000502
NFT tau neurofibrillary tangle IPR002955 0
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t h e r ei sav e r yl o wr a t eo fe i t h e rA b production or tau
phosphorylation. Figure 3E shows the mean levels and
standard deviations from 100 simulations and it can be
seen that this is similar to the results of a deterministic
simulation (see Figure 3F) using Cell Designer [32].
Note that the standard deviation is very low for most of
the model species apart from total p53 and total Mdm2
levels. The larger variability in levels of p53 and Mdm2
is due to the fluctuations in protein levels occurring at
slightly different time-points in each simulation.
Stressed conditions
To mimic the experimental procedure of irradiating
cells, we used a discrete time event to increase the value
of the dummy species IR, which represents irradiation,
to 25 dGy, for a period of 1 minute. This results in
damaged DNA as can be seen in Figure 4. The damaged
DNA activates ATM which results in phosphorylation
of p53 and Mdm2 and the model predicts oscillations of
both proteins as in our previous model (compare Figure
11 of Proctor & Gray, 2008[26] with Figure 4 below).
Since p53 levels increase, more GSK3b is able to bind to
p53 and there is a slight increase in Ab and phosphory-
lated tau but no aggregation within the time scale simu-
lated. If we simulate the model under stress conditions
for longer time periods, then the oscillations die away as
the damaged DNA is repaired. This is followed by clear-
ance of Ab and dephosphorylation of tau and so no
aggregation will take place.
Decline in repair capacity
I no r d e rt oe x a m i n ew h e t h e ra g g r e g a t i o nw o u l do c c u ri f
DNA damage persisted we decreased the rate of DNA
repair by an order of magnitude and simulations were
run for 8 days. In this case, the model predicts that aggre-
gates of Ab and tau slowly start to accumulate (Figure 5).
Since they are irreversible at this stage, they will persist
even when DNA damage is eventually repaired. In some
simulations, DNA damage starts to increase again (e.g.
Figure 5B). We have also plotted ROS levels in Figure 5
and it can be clearly seen that in the simulations where
DNA damage increases, there is also an increase in ROS
due to the toxic effects of the aggregates.
Increased aggregation rate
If the model with parameters for normal conditions was
simulated for a very long period of time, eventually we
would expect that either Ab or tau might start to accumu-
late by chance in some cells due to stochastic effects.
Many runs would be required over long periods of time to
observe this and so would be very computer intensive.
Therefore, to speed up the process, we increased the rate
at which either Ab or tau aggregates by two orders of
magnitude and ran simulations for a period of 12 days.
Figure 6 shows that there is quite a lot of cell variability
with 1 cell showing no increase in aggregation but with an
increase in aggregation in the other 4 simulated cells. We
f o u n dt h a ta b o u t2 4 %o fc e l l sd on o ta c c u m u l a t eD N A
damage from the model output of 100 simulations and in
these cells there is no increase in p53 levels, GSK3b activ-
ity, tau phosphorylation or an increase in Ab. The time at
which aggregates start to from is very variable with about
50% of simulated cells without any plaques by 8 days,
whereas two cells start to form plaques by day 3. The
model output suggests that stochastic effects in protein
levels lead to an increase in levels of p53 which binds to
GSK3b and so activity of both p53 and GSK3b increase.
This leads to phosphorylation of tau which then starts to
aggregate, and also an increase in Ab levels. The increase
in aggregation leads to increase levels of ROS and so DNA
damage rates increase resulting in stabilisation of p53.
Finally the activity of p53 and GSK3b increases further,
leading to even more aggregation and a vicious cycle
ensues. Note that the variance of p53 and Mdm2 increases
with time in these simulations (Figure 6F). This is due to
the levels of both proteins increasing with time in the
majority of simulated cells and a small proportion of cells
with low levels of these proteins throughout the
simulation.
Interestingly, the model predicts that tau tangles start to
form prior to Ab plaques but that once Ab plaques start
to form they rapidly increase in size. Since aggregates can
only be detected when they are a certain size, this might
explain why Ab plaques are often detected before tau tan-
gles [33]. According to the model, the formation of tau
tangles and Ab plaques are independent events but both
occur as a result of the increased activity of GSK3b.T h e s e
points are discussed in more detail below.
Table 1: List of model species (Continued)
PP1 phosphatase P62136 50
ATP Adenosine triphosphate CHEBI:15422 10000
ADP Adenosine diphosphate CHEBI:16761 1000
AMP Adenosine monophosphate CHEBI:22254 1000
Terms starting with:
P or Q are from UniProtKB/Swiss-Prot [40], SBO are from Systems Biology Ontology [41], CHEBI are from Chemical Entities of Biological Interest Database [42], GO
are from Gene Ontology [43], IPR are from Interpro [44]
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No. Name Reactants and products Kinetic Law
a Parameter value
1 GSK3b_p53Binding GSK3b+p53®
GSK3b_p53
kbinGSK3bp53<#GSK3b><#p53> 2.0E-6 molecule
-1 s
-1
2 GSK3b_p53Release GSK3b_p53® GSK3b+p53 krelGSK3bp53<#GSK3b_p53> 2.0E-3 s
-1
(1) GSK3b_p53_PBinding GSK3b+p53_P®
GSK3b_p53_P
kbinGSK3bp53<#GSK3b><#p53_P> 2.0E-6 molecule
-1 s
-1
(2) GSK3b_p53_PRelease GSK3b_p53_P® GSK3b+p53_P krelGSK3bp53<#GSK3b_p53_P> 2.0E-3 s
-1
3 Mdm2mRNASynthesis3 GSK3b_p53®
GSK3b_p53+Mdm2mRNA
ksynMdm2mRNAGSK3bp53<#GSK3b_p53> 7.0E-4 s
-1
(3) Mdm2mRNASynthesis4 GSK3b_p53_P®
GSK3b_p53_P+Mdm2mRNA
ksynMdm2mRNAGSKbp53<#GSK3b_p53_P> 7.0E-4 s
-1
4 Mdm2GSK3phosphorylation1 Mdm2_p53_Ub4+GSK3b® Mdm2_P1_p53_Ub4
+GSK3b
kphosMdm2GSK3b<#Mdm2_p53_Ub4>
<#GSK3b>
5.0E-3 molecule
-1 s
-1
5 Mdm2GSK3phosphorylation2 Mdm2_p53_Ub4+GSK3b_p53 ®
Mdm2_P1_p53_Ub4 +GSK3b_p53
kphosMdm2GSK3bp53<#Mdm2_p53_Ub4>
<#GSK3b_p53>
5.0E-1 molecule
-1 s
-1
(5) Mdm2GSK3phosphorylation3 Mdm2_p53_Ub4+GSK3b_p53_P®
Mdm2_P1_p53_Ub4+GSK3b_p53_P
kphosMdm2GSK3bp53<#Mdm2_p53_Ub4>
<#GSK3b_p53_P>
5.0E-1 molecule
-1 s
-1
6 TauSynthesis Source®Tau ksynTau 8.0E-5 molecule s
-1
7 TauProteasomeBinding Tau+Proteasome®Proteasome_Tau kbinTauProt<#Tau><#Proteasome> 1.9E-7 molecule
-1 s
-1
8 TauDegradation Proteasome_Tau®Proteasome kdegTau<#Proteasome_Tau> 1.0E-2 s
-1
9 TauMTbinding Tau®MT_Tau kbinMTTtau<#Tau> 1.0E-1 s
-1
10 TauMTrelease MT_Tau®Tau krelMTTau<#MT_Tau> 1.0E-4 s
-1
11 Tauphosphorylation1 GSK3b_p53+Tau®GSK3b_p53+Tau_P1 kphospTauGSK3bp53<#GSK3b_p53><#Tau> 1.0E-1 molecule
-1 s
-1
(11) Tauphosphorylation2 GSK3b_p53+Tau_P1®GSK3b_p53+Tau_P2 kphospTauGSK3bp53<#GSK3b_p53>
<#Tau_P1>
1.0E-1 molecule
-1 s
-1
(11) Tauphosphorylation3 GSK3b_p53_P+Tau®GSK3b_p53_P+
Tau_P1
kphospTauGSK3bp53<#GSK3b_p53_P><#
Tau>
1.0E-1 molecule
-1 s
-1
(11) Tauphosphorylation4 GSK3b_p53_P + Tau_P1®GSK3b_p53_P+
Tau_P2
kphospTauGSK3bp53<# GSK3b_p53_P>
<#Tau_P1>
1.0E-1 molecule
-1 s
-1
12 Tauphosphorylation5 GSK3b+Tau®GSK3b+Tau_P1 kphospTauGSK3b<#GSK3b><#Tau> 2.0E-4 molecule
-1 s
-1
(12) Tauphosphorylation6 GSK3b+Tau_P1®GSK3b+Tau_P2 kphospTauGSK3b<#GSK3b><#Tau_P1> 2.0E-4 molecule
-1 s
-1
(13) Taudephosphorylation1 Tau_P2+PP1®Tau_P1+PP1 kdephospTau<#Tau_P2><#PP1> 1.0E-2 molecule
-1 s
-1
14 TauAggregation1 2Tau®2AggTau kaggTau<# Tau><#(Tau-1)>/2.0 1.0E-8 molecule
-1 s
-1
(14) TauAggregation2 Tau+AggTau®2AggTau kaggTau<#Tau><#AggTau> 1.0E-8 molecule
-1 s
-1
15 TauP1Aggregation1 2Tau_P1®2AggTau kaggTauP1 <#Tau_P1><#(Tau_P1-1)>/2.0 1.0E-8 molecule
-1 s
-1
(15) TauP1Aggregation2 Tau_P1+AggTau®2AggTau kaggTauP1 <# Tau_P1><#AggTau> 1.0E-8 molecule
-1 s
-1
(15) TauP2Aggregation1 2Tau_P2®2AggTau kaggTauP2 <#Tau_P2><# (Tau_P2-1)
>/2.0
1.0E-7 molecule
-1 s
-1
(15) TauP2Aggregation2 Tau_P2 + AggTau®2AggTau kaggTauP2 <#Tau_P2><# AggTau> 1.0E-7 molecule
-1 s
-1
16 TangleFormation1 2AggTau®2NFT ktangfor<#AggTau><#(AggTau-1)>/2.0 1.0E-3 molecule
-1 s
-1
(16) TangleFormation2 AggTau+NFT®2NFT ktangfor<#AggTau><#NFT> 1.0E-3 molecule
-1 s
-1
17 ProteasomeInhibitionAggTau AggTau+Proteasome®
AggTau_Proteasome
kinhibprot<#AggTau><#Proteasome> 1.0E-5 molecule
-1 s
-1
18 Abetaproduction1 GSK3b_p53®Abeta+GSK3b_p53 kprodAbeta<#GSK3b_p53> 5.0E-5 s
-1
(18) Abetaproduction2 GSK3b_p53_P®Abeta
+GSK3b_p53_P
kprodAbeta<#GSK3b_p53_P> 5.0E-5 s
-1
19 AbetaDegradation Abeta®Sink kdegAbeta<#Abeta> 1.0E-4 s
-1
20 AbetaAggregation1 2Abeta®AggAbeta kaggAbeta<#Abeta><#(Abeta-1)>/2.0 1.0E-8 molecule
-1 s
-1
(20) AbetaAggregation2 Abeta+AggAbeta®2AggAbeta kaggAbeta<#Abeta><#AggAbeta> 1.0E-8 molecule
-1 s
-1
21 AbetaPlaqueFormation1 2AggAbeta®2AbetaPlaque kpf <#AggAbeta><#(AggAbeta-1)>/2.0 1.0E-3 molecule
-1 s
-1
(21) AbetaPlaqueFormation2 AggAbeta+AbetaPlaque®2AbetaPlaque kpf <#AggAbeta><#AbetaPlaque> 1.0E-3 molecule
-1 s
-1
22 ProteasomeInhibitionAbeta AggAbeta+Proteasome®
AggAbeta_Proteasome
kinhibprot<#AggAbeta><#Proteasome> 1.0E-5 molecule
-1 s
-1
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We also performed simulations with either GSK3b or
p53 deleted from the model to examine whether the
interaction between GSK3b and p53 was necessary to
obtain aggregation of Ab and tau. In order to do this it
was necessary to make some slight modifications to our
model. As we had assumed that phosphorylation of
Mdm2 by GSK3b was necessary for p53 degradation,
the model would predict that p53 levels would increase
with time if there is no GSK3b. Therefore we added a
reaction of p53 binding to the proteasome without
Mdm2 phosphorylation but assumed that this happened
at a much lower rate. The GSK3b showed similar results
to the original model with regards to p53 oscillations
after DNA damage (data not shown). However, if we
run the model without the irradiation event and
increase the aggregation rates of tau and Ab by two
orders of magnitude, then the model predicts that no
aggregation takes place by 12 days indicating that
GSK3b activity is necessary for tangle and plaque forma-
tion in this model (data not shown).
For the p53 null model, we added a reaction to allow
Ab formation via GSK3b even when it is not bound to
p53. We assumed that this occurred at a rate kbasalprodA-
beta = 1.0E-7, (which is five hundred times lower than
kprodAbeta, the rate corresponding to Ab production by
GSK3b which is bound to p53). We ran the model
under conditions of no irradiation and high aggregation
rates and found that GSK3b had to be increased 20-fold
to get similar levels of plaques and tangles as seen in
Figure 6 (data not shown). Therefore, although p53 is
not essential for aggregation to take place, our model
predicts that p53 has a substantial effect on the kinetics
of aggregation. These predictions could be tested in the
laboratory.
Discussion
We extended the model of Proctor & Gray (2008) [26]
to include details of p53 and Mdm2 ubiquitination, the
interaction of p53 with GSK3b and the activity of
GSK3b. As we had used SBML to build the models, it
was straight forward to make the necessary modifica-
tions. As in our previous model, we find that a sudden
increase in DNA damage leads to oscillations of p53
and Mdm2. Our new model shows that the disruption
of the Mdm2/p53 complex, allows the formation of
GSK3b/p53 complexes which results in increased tran-
scriptional activity of p53 and increased kinase activity
of GSK3b. The result is an increase in Ab production,
an increase in Mdm2 mRNA and an increase in tau
phosphorylation. Under normal conditions, the model
predicts that Ab is cleared from cells and so does not
accumulate, and tau is dephosphorylated to maintain
the correct balance of phosphorylated and unphosphory-
lated tau. However, after a stress event, the DNA
damage response leads to increased activity of p53 and
GSK3b which results in increased production of Ab and
increased phosphorylation of tau. However, the para-
meter for DNA repair was set so that most DNA
damage is repaired by 24 hours, and then Ab is cleared
and tau is dephosphorylated so that aggregates do not
accumulate. In the ageing brain we would expect that
DNA damage might sometimes persist either due to a
decline in repair mechanisms or an increase in ROS
production. We used our model to examine the out-
come of a deficiency in DNA repair. In this case, we
find that aggregates are much more likely to accumulate
which in turn lead to increased ROS production and
further DNA damage which leads to further activation
of p53 and GSK3b and even more aggregation.
We also used the model to examine cellular outcomes
which would be more typical of ageing, where the accu-
mulation of DNA damage and other types of cellular
damage is more gradual. As stochastic computer simula-
tions take a long time to run, we increased the aggrega-
tion rates so that the model could be run for a
reasonably short time period. Without a major dama-
ging event, stochastic events become much more impor-
tant and we see considerable variation in the time at
which damage starts to accumulate. We also noted that
our model predicted that tau tangles start to form
before Ab plaques but that levels of these plaques soon
overtake those of tau tangles due to their more rapid
increase at the elongation stage. Our results might seem
contradictory to experimental data and the amyloid cas-
cade hypothesis [34]. However, aggregates need to reach
a certain size to be detectable whereas our model output
can detect aggregates as soon as formation begins. If we
also imposed a threshold of detection on our model out-
put, we would see Ab plaques before tau tangles in
Table 2: Reactions involving Gsk3b,A b and tau (Continued)
23 p53transcriptionViaAbeta Abeta®p53_mRNA+Abeta ksynp53mRNAAbeta<#Abeta> 1.0E-5 s
-1
24 AbetaROSproduction1 AggAbeta®AggAbeta + ROS kgenROSAbeta<#AggAbeta> 1.0E-5 s
-1
24 AbetaROSproduction2 AggAbeta_Proteasome®AggAbeta_Proteasome
+ ROS
kgenROSAbeta<#AggAbeta_Proteasome> 1.0E-5 s
-1
a <#X> means number of molecules of species X
We assume that the reaction volume is equal to one.
Reactions with number in 1
st column are shown in Figure 2; reactions with numbers in parentheses are similar to the reactions shown in Figure 2.
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Page 9 of 15Table 3 Reactions involved in p53 turnover and the DNA damage response
No. Name Reactants and products Kinetic law
a Parameter values
25 p53 synthesis p53_mRNA®p53+p53_mRNA ksynp53 <#p53_mRNA> 7.0E-3 s
-1
26 p53 Mdm2 binding p53+Mdm2 ® Mdm2_p53 kbinMdm2p53<#p53><#Mdm2> 3.0E-3 molecule
-1 s
-1
27 Mdm2_p53 release Mdm2_p53®p53+Mdm2 krelMdm2p53 <#Mdm2_p53> 3.0E-5 s
-1
E1/Ub binding E1+Ub+ATP®E1_Ub+AMP kbinE1Ub <#E1><#Ub><#ATP>/(5000 +<#ATP>) 2.0E-4 molecule
-1 s
-1
E2/Ub binding E1_Ub+E2®E2_Ub+E1 kbinE2Ub<#E2><#E1_Ub> 1.0E-3 molecule
-1 s
-1
28 p53 ubiquitination
Mdm2_p53+E2_Ub®Mdm2_p53_Ub+E2
kp53Ub<#Mdm2_p53><#E2_Ub> 5.0E-5 molecule
-1 s
-1
29 p53
polyubiquitination1
Mdm2_p53_Ub+E2_Ub®Mdm2_p53_
Ub2+E2
kp53PolyUb<#Mdm2_p53_Ub><#E2_Ub> 1.0E-2 molecule
-1 s
-1
30 p53
polyubiquitinationX
(X = 2-3)
Mdm2_p53_Ub(X)+E2_Ub®
Mdm2_p53_Ub(X+1)+E2
kp53PolyUb<#Mdm2_p53_Ub(X)><#E2_Ub> 1.0E-2 molecule
-1 s
-1
p53 de-ubiquitination1 Mdm2_p53_Ub+p53DUB ®
Mdm2_p53+p53DUB+Ub
kactDUBp53<#Mdm2_p53_Ub>
<#p53DUB>
1.0E-7 molecule
-1 s
-1
p53 de-ubiquitinationX
(X = 2-4)
Mdm2_p53_Ub(X)+p53DUB ®
Mdm2_p53_Ub(X-1)+p53DUB+Ub
kactDUBp53<#Mdm2_p53_Ub(X)>
<#p53DUB>
1.0E-7 molecule
-1 s
-1
31 p53 Proteasome
binding
Mdm2_P_p53_Ub4+Proteasome®
p53_Ub4_Proteasome+Mdm2
kbinProt<# Mdm2_P_p53_Ub4><#Proteasome> 2.0E-6 molecule
-1 s
-1
32 p53 degradation p53_Ub4_Proteasome+ATP®
4Ub+Proteasome+ADP
kdegp53<#p53_Ub4_Proteasome> <#ATP>/(5000
+ <#ATP>)
1.0E-2 s
-1
33 Mdm2mRNA
synthesis1
p53®p53+Mdm2_mRNA ksynMdm2mRNA<#p53> 5.0E-4 s
-1
(33) Mdm2mRNA
synthesis2
p53_P®p53_P+Mdm2_mRNA ksynMdm2mRNA<#p53_P> 5.0E-4 s
-1
34 Mdm2 mRNA
degradation
Mdm2_mRNA®Sink kdegMdm2mRNA<#Mdm2_mRNA> 5.0E-4 s
-1
35 Mdm2 synthesis Mdm2_mRNA®Mdm2_mRNA+Mdm2 ksynMdm2<#Mdm2_mRNA> 4.95E-4 s
-1
Mdm2 ubiquitination
b Mdm2+E2_Ub®Mdm2_Ub+E2 kMdm2Ub<#Mdm2><#E2_Ub> 4.56E-6 molecule
-1 s
-1
Mdm2
polyubiquitination1
c
Mdm2_Ub+E2_Ub®Mdm2_Ub2+E2 kMdm2PolyUb<#Mdm2_Ub><#E2_Ub> 4.56E-3 molecule
-1 s
-1
Mdm2
polyubiquitinationX
c
(X = 2-3)
Mdm2_Ub(X)+E2_Ub®Mdm2_Ub(X+1)+E2 kMdm2PolyUb<#Mdm2_Ub(X)><#E2_Ub> 4.56E-3 molecule
-1 s
-1
Mdm2 de-
ubiquitination1
c
Mdm2_Ub+Mdm2DUB ®
Mdm2+Mdm2DUB+Ub
kactDUBMdm2<#Mdm2_Ub><#Mdm2DUB> 1.0E-7 molecule
-1 s
-1
Mdm2 de-
ubiquitinationX
c
(X = 2-4)
Mdm2_Ub(X)+Mdm2DUB ®
Mdm2_Ub(X-1)+Mdm2DUB+Ub
kactDUBMdm2<#Mdm2_Ub(X)>
<#Mdm2DUB>
1.0E-7 molecule
-1 s
-1
Mdm2 proteasome
binding
c
Mdm2_Ub4 +
Proteasome®Mdm2_Ub4_Proteasome
kbinProt<# Mdm2_Ub4><#Proteasome> 2.0E-6 molecule
-1 s
-1
Mdm2 degradation
c Mdm2_Ub4_Proteasome+ATP®
4Ub+Proteasome+ADP
kdegMdm2<#Mdm2_Ub4_Proteasome>
<#ATP>/(5000+<#ATP>)
1.0E-2 molecule
-1 s
-1
36 ATM activation damDNA+ATMI®damDNA+ATMA kactATM<#damDNA><#ATMI> 1.0E-4 molecule
-1 s
-1
37 ATM inactivation ATMA ® ATMI kinactATM<#ATMA> 5.0E-4 s
-1
38 p53 phosphorylation p53+ATMA®p53_P+ATMA kphosp53<#p53><#ATMA> 2.0E-4 molecule
-1 s
-1
39 p53 dephosphorylation p53_P®p53 kdephosp53<#p53_P> 5.0E-1 s
-1
Mdm2
phosphorylation
Mdm2+ATMA®Mdm2_P+ATMA kphosMdm2<#Mdm2><#ATMA> 2.0 molecule
-1 s
-1
Mdm2 de-
phosphorylation
Mdm2_P®Mdm2 kdephosMdm2<#Mdm2_P> 5.0E-1 s
-1
40 p53mRNA synthesis Source®p53_mRNA ksynp53mRNA 1.0E-3 molecule s
-1
41 p53mRNA degradation p53_mRNA®Sink kdegp53mRNA<#p53_mRNA> 1.0E-4 s
-1
42 DNA damage by IR IR®damDNA+ IR kdam<#IR> 8.0E-2 s
-1
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Page 10 of 15some simulations, depending on the threshold chosen.
Most importantly, our model suggests that the forma-
tion of plaques and tangles are independent events, but
that they share a common cause, namely GSK3b
overactivity.
The output from our model showed that even when
p53 levels rose after DNA damage, they were prevented
from rising indefinitely by the action of the negative
feedback loop involving Mdm2. However, due to ran-
dom fluctuations in protein levels, it is possible that p53
levels would sometimes rise to levels which would
exceed the threshold required to activate apoptotic path-
ways. In this case neuronal death would take place. Our
model predicted that this was much more likely to
occur when protein aggregates start to accumulate and
the proteasome becomes inhibited due to less efficient
turnover of p53. Interestingly studies have shown that
AD patients have a lower incidence of several types of
cancer [35]. So although high levels of p53 are detri-
mental in the ageing brain due to neuronal loss, an
increase in apoptosis prevents cancer.
We used the model to test the effects of deleting
either p53 or GSK3b to examine whether the interaction
between GSK3b and p53 was necessary to obtain aggre-
gation to Ab and tau. The model shows that GSK3b is
required for aggregation to take place when p53 is pre-
s e n tb u tt h a ti tw a sp o s s i b l ef o ra g g r e g a t e st of o r mi n
the absence of p53, providing that GSK3b was highly
expressed. A number of experiments are planned to test
the model predictions. If the vicious cycle hypothesis is
correct, the self-amplifying cycle of GSK3b/p53 activa-
tion should be critically dependent on both entities and
should not occur when one or both are inactivated or
deficient. It should be possible to monitor the status of
protein aggregates, tau phosphorylation, and proteasome
inhibition in cultured cells irradiated to induce DNA
Figure 3 Model output for normal (unstressed) conditions. A-D Four individual simulations over 30 hour time period. E Mean (solid lines)
and standard deviation (dashed lines) of 100 simulations. F Deterministic solution from Cell Designer. All parameter values used are given in
Tables 2 and 3. Levels of p53 (total pool, including bound and ubiquitinated species), Mdm2 (total pool, including bound and ubiquitinated
species), p53 bound to GSK3b, damaged DNA (damDNA), Ab plaques and Tau tangles are shown. Key: green line: p53, red line: Mdm2, gray line:
GSK3b_p53, purple line: damaged DNA, blue line: Tau tangles, cyan line: Abeta plaques.
Table 3: Reactions involved in p53 turnover and the DNA damage response (Continued)
43 DNA repair damDNA®Sink krepair<#damDNA> 2.0E-5 s
-1
44 DNA damage by ROS ROS®damDNA+ROS kdamROS<#ROS> 1.0E-5 s
-1
(44) DNA damage by
basalROS
basalROS®damDNA+ basalROS kdambasalROS<#basalROS> 1.0E-9 s
-1
a <#X> means number of molecules of species X,
bMdm2_P is also ubiquitinated in the same way but the first step occurs at a higher rate (kMdm2PUb = 6.84E-6).
cMdm2_P undergoes polyubiquitination, de-ubiquitination, binding to the proteasome and degradation at the same rate as Mdm2. We assume that the reaction
volume is equal to one. Reactions with number in 1
st column are shown in Figure 2; reactions with numbers in parentheses are similar to the reactions shown in
Figure 2.
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Page 11 of 15Figure 5 Model output for less efficient DNA repair. A-E Five simulations over 8 day time period. F Mean (solid lines) and standard deviation
(dashed lines) of 100 simulations. An event to mimic irradiation took place 1 hour after the start of the simulation. The parameter for DNA repair
was reduced by an order of magnitude (krepair = 2.0E-6). All other parameter values used are given in Tables 2 and 3. Levels of p53 (total pool,
including bound and ubiquitinated species), Mdm2 (total pool, including bound and ubiquitinated species), p53 bound to GSK3b, damaged DNA
(damDNA), ROS levels (scaled by a factor of 5 to be seen more clearly), Ab plaques and Tau tangles are shown. Key: green line: p53, red line:
Mdm2, gray line: GSK3b_p53, purple line: damaged DNA, blue line: Tau tangles, cyan line: Abeta plaques, black line: ROS levels ×5.
Figure 4 Model output for stressed conditions. A-E Five simulations over 30 hour time period. F Mean (solid lines) and standard deviation
(dashed lines) of 100 simulations. An event to mimic irradiation took place 1 hour after the start of each simulation. All parameter values used
are given in Tables 2 and 3. Levels of p53 (total pool, including bound and ubiquitinated species), Mdm2 (total pool, including bound and
ubiquitinated species), p53 bound to GSK3b, damaged DNA (damDNA), Ab plaques and Tau tangles are shown. Key: green line: p53, red line:
Mdm2, gray line: GSK3b_p53, purple line: damaged DNA, blue line: Tau tangles, cyan line: Abeta plaques.
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p53 or in conditions where a component is inhibited
(for example by the GSK3b inhibitor alsterpaullone) or
missing (as in cells derived from p53 null mice). The
predicted role of accumulating DNA damage in trigger-
ing the GSK3b/p53 vicious cycle can be tested in cells
that are genetically deficient in DNA repair components
or in normal cells chronically exposed to DNA dama-
ging agents. It will also be informative to carry out
experiments with GSK3b and p53 over-expression
together to see if there is enhanced Ab production or
accumulation of tau. The outcome of these experiments
will be reported in a future publication.
This model only examines a very small part of the
cellular system. In reality there are many pathways and
many other components that we have not considered
here. For example, the chaperone system is very
important in maintaining protein homeostasis by bind-
ing to misfolded protein and assisting in either refold-
ing or elimination of the damaged protein.
Mitochondria also play an important role as they pro-
duce the ATP required for many cellular processes
such as protein degradation. They also produce ROS
as a by-product of respiration. Mitochondria, them-
selves are susceptible to oxidative damage and this can
lead to increased levels of ROS. Other models are
being developed where the emphasis is on using a sys-
tems biology approach.
When we simulated the effects of an increased aggre-
gation rate without any initial DNA damaging event, we
in effect speeded up the ageing process. Care is needed
in interpreting these results as they could give the false
impression that aggregation might occur at an early age.
However, in reality, it is unlikely that protein homeosta-
sis would be disturbed until old age, which is why only
people over a certain age get Alzheimer’sd i s e a s e .H o w -
ever, there is considerable variation in the actual age of
disease onset which may be mainly due to stochastic
effects as our model suggests.
The model was kept as simple as possible but included
enough detail to make some meaningful predictions. We
only included degradation of unphosphorylated tau by
the 20S proteasome in a ubiquitin-independent manner.
Although phosphorylated tau is resistant to degradation
by proteases [36], it has been shown that phosphorylated
tau is degraded by ubiquitin-dependent proteasome path-
way and the heat shock proteins Hsp70, Hsp70, the ubi-
quitin ligase CHIP and the kinase Akt are all involved
[37-39]. More detailed models of Ab and tau turnover
which also contain more detail of the aggregation process
are being developed and these could be easily incorpo-
rated in the current GSK3b/p53 model. We did not
include turnover of GSK3b since GSK3b is relatively
Figure 6 Model output for increased aggregation rate. A-E Five simulations over 12 day time period. F Mean (solid lines) and standard
deviation (dashed lines) of 100 simulations. No irradiation. The parameters for aggregation were increased by two orders of magnitude. (kaggTauP
= kaggTauP1 = kaggAbeta = 1.0E-6, kaggTauP2 = 1.0E-5). All other parameter values used are given in Tables 2 and 3. Levels of p53 (total pool,
including bound and ubiquitinated species), Mdm2 (total pool, including bound and ubiquitinated species), p53 bound to GSK3b, damaged DNA
(damDNA), Ab plaques and Tau tangles are shown. Key: green line: p53, red line: Mdm2, gray line: GSK3b_p53, purple line: damaged DNA, blue
line: Tau tangles, cyan line: Abeta plaques.
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Page 13 of 15stable but over long time periods it could start to accu-
mulate if the proteasome became inhibited and so it may
be desirable to add detail of GSK3b turnover. Interest-
ingly Hsp90 is also involved in maintaining the stability
of GSK3b [30]. Furthermore, there are many other path-
ways leading to activation of GSK3b, such as deregulation
of the insulin and Wnt pathways. Our current model
could be used to examine cellular outcomes by assuming
that if p53 reached above a certain threshold, apoptosis
would take place. Alternatively we could further extend
the model to include pathways leading to cell death. This
would be a very useful addition to the model as neuronal
loss is a common feature of neurodegenerative disorders
but it occurs only in subsets of neurons in specific
regions of the brain.
Conclusions
Our model predicts that GSK3b overactivity leads to
an increase in levels of Ab plaques and tau tangles by
independent processes suggesting that the observed
correlation between plaques and tangles may not be
due to a causal relationship. The interaction of GSK3b
with p53 leads to increase activity of both proteins.
Since p53 and GSK3b are both involved in the apopto-
tic pathway, and GSK3b overactivity leads to increased
levels of plaques and tangles, our model might explain
the link between protein aggregation and neuronal loss
in neurodegeneration. Therefore modulating the inter-
action of GSK3b a n dp 5 3m a yb eau s e f u lt h e r a p e u t i c
strategy.
Additional file 1: SBML code for GSK3-p53 model with IR event. This
file contains the SBML code for the model with the event for IR
included.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-1326-5-7-
S1.XML]
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